SOCIUM Inc. With a core mission of Drug discovery for patients with no drug, Drug discovery for patients with ineffective drug, SOCIUM is committed to partnering with individuals who aspire to lead healthier lives. SOCIUM actively addresses the challenges faced by pharmaceutical partners by contributing to drug research and development.

By revolutionizing the drug discovery process, they strive to identify and develop effective medicines for patients who have limited or no treatment options. Furthermore, their dedication extends to collaborating with pharma partners to provide innovative medications to patients at an earlier stage. Led by President and CEO Hiroshi Kawai and supported by a stellar team, including co-founder and CTO Katsuhisa Horimoto, and outside director Atsushi Usami, SOCIUM has made remarkable strides in the field.

Their areas of expertise encompass Phenotypic Network Screening, Drug Repurposing, Phosphorylation Analysis, MOA Clarification, and Stratification Marker Exploration. Located at offices in Chuo-ku and Koto-ku, Tokyo, SOCIUM is pioneering breakthroughs in drug discovery and making milestone contributions to healthcare